Amino Recovery Blend
EAA/amino stack (Arg, Citrulline, Ornithine, Glutamine, Glycine, Lysine, BCAA 2:1:1, Taurine)
Amino Recovery Blend (EAA/amino stack (Arg, Citrulline, Ornithine, Glutamine, Glycine, Lysine, BCAA 2:1:1, Taurine)) is a healing & recovery research compound. Recovery amino-acid matrix — arginine/citrulline/ornithine drive nitric oxide and the urea cycle, BCAAs and glutamine support muscle protein synthesis and recovery, glycine and taurine add cellular and antioxidant support.
Amino Recovery Blend quick facts
| Reported research dose | As directed (20mL vial) |
| Route | Subq |
| Frequency | As directed |
| Half-life | Varies by component |
| Forms | Injectable |
| Evidence level | Blend (component-based) |
Full recovery amino stack in one shot — NO/pump support plus the building blocks for repair.
How Amino Recovery Blend works
Recovery amino-acid matrix — arginine/citrulline/ornithine drive nitric oxide and the urea cycle, BCAAs and glutamine support muscle protein synthesis and recovery, glycine and taurine add cellular and antioxidant support.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Where to get Amino Recovery Blend
Buy Amino Recovery Blend at AminoWell USA →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Amino Recovery Blend
Graded by what exists behind each claim.
✅ Clinically validated
- No trial of the blend. Amino acid and BCAA supplementation has a large human literature, and the honest summary is that benefits appear where total protein intake is inadequate and largely disappear where it is not.
📊 Correlative data
- Used peri-workout for recovery. Reported experience is hard to separate from training and diet, which is the perennial problem with recovery products.
🧪 Theoretical / extrapolated
- Supplies substrate for muscle protein synthesis, with leucine as the specific trigger for mTOR activation.
- Substrate is rarely the limiting factor in someone eating enough protein, which is the mechanistic reason the trials look the way they do. The strongest case is convenience and timing rather than a unique effect.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Amino Recovery Blend actually does
This is not one compound, it is eight molecules that already exist in your blood, and the only question worth asking is how many milligrams of each a 20 mL vial can carry. Arginine, citrulline and ornithine are urea-cycle intermediates. Leucine, isoleucine and valine are the branched-chain essential amino acids. Glutamine, glycine and taurine are the three most abundant free amino acids in human muscle. Every one of them is a normal dietary constituent measured in grams per meal, so the mechanism question here is not “what does arginine do” — it is whether an injectable dose is on the same scale as the pool it is joining. It is not, and the rest of this page follows from that.
The arithmetic, done out loud, because nobody does it. A solution meant for subcutaneous injection has to stay near physiological tonicity or it stings and leaves a lump. Free amino acids are osmotically active small molecules, roughly 100–200 daltons each, so a solution containing 5 g per 100 mL is already several hundred milliosmoles above plasma before anything else is added. Take that as a generous ceiling: a 20 mL vial at 5% total amino acid holds about 1 gram, split eight ways. A 1–2 mL subcutaneous shot from that vial delivers 50–100 mg of amino acid in total. A 30 g whey shake delivers roughly 2.5–3 g of leucine alone — thirty to sixty times the entire injection, from one ingredient.
So this cannot work by mass action, and that is a finding rather than a criticism. If it does anything, it has to do it as a signal, not as substrate. Three of the eight have a plausible signaling story at low dose. Arginine is the substrate for nitric oxide synthase. Leucine is the amino acid mTORC1 senses through Sestrin2, and sensing is a receptor-like event with a saturable response, not a stoichiometric one. Taurine is an osmolyte and a modulator of calcium handling. Glutamine, glycine, valine, isoleucine and ornithine at 10 mg each are joining a circulating pool measured in hundreds of micromoles per liter, and the honest expectation for those five is no measurable change in anything .
The arginine paradox is the one piece of real pharmacology here, and it argues for the needle. Oral arginine is a poor way to raise plasma arginine, because intestinal and hepatic arginase degrade a large share of the dose before it reaches the systemic circulation. That is exactly why citrulline exists as a supplement: citrulline escapes arginase, is taken up by the kidney and converted to arginine there, and therefore raises plasma arginine more efficiently than arginine itself Maric 2021. Injecting arginine bypasses the same first-pass problem by a different route. Which means a blend that contains both arginine AND citrulline is paying an injection cost for the one component that already had an oral workaround.
Cell, rodent, human — and where it stops
Step one, the biochemistry, which is not in question. Amino acid metabolism in health and disease is one of the best-mapped areas in human biology — the transporters, the transaminases, the regulatory nodes and the disease states are all characterized Ling 2023. Nothing on this page depends on any of that being wrong.
Step two, in people, on the muscle claim. The relevant human literature is not about injections; it is about whether adding amino acids to a diet changes muscle mass. A systematic review and meta-analysis of nutritional interventions in older adults set out to find what makes such interventions work Martin-Cantero 2021, and the pattern across that literature is consistent: benefit appears where baseline protein intake is inadequate, and shrinks toward zero where it is not. The Vault's own evidence block for this product says the same thing, and it is the correct summary.
Step three, and this is the step that decides the page: does delivery route change the answer? Human work on amino acid kinetics shows that the SHAPE of the plasma appearance curve is a real variable, not a detail — the same amino acid profile delivered from a slower-appearing matrix produced lower peripheral amino acid appearance than whey in healthy older adults, despite the profile being matched on paper de Marco Castro 2022. A subcutaneous injection would in principle give the fastest, cleanest appearance curve of any route, because it skips the gut entirely. The obstacle is that a fast curve on 50 mg is still 50 mg. Nobody has published an appearance curve, a nitrogen balance, or a muscle protein synthesis measurement for a subcutaneous mixed amino acid bolus at this scale, in any population.
Step four, what the subcutaneous route IS known to do. It works for volume and for small molecules: a systematic review of systematic reviews found strong evidence supporting subcutaneous administration for 10 medications, weak evidence for 28 and inconclusive evidence for eight Broadhurst 2020, and a trial of subcutaneous acetaminophen in geriatric and palliative care tested the route directly El Khoury 2022. So the route is real medicine. It is simply being asked here to deliver a nutrient at a dose the nutrient is not used at.
Amino Recovery Blend pharmacokinetics — how much of it actually gets in
The card says “varies by component,” which is true and also the end of the thought. Here is the arithmetic behind it.
Nothing here is degraded by a cytochrome. Amino acids do not have a half-life in the drug sense at all — they are not cleared, they are absorbed into a pool and then transaminated, oxidized or built into protein. The relevant clearance term for arginine is arginase, which is an amidase-class hydrolase that splits it to ornithine and urea; for the branched-chain amino acids it is the BCAT transaminase followed by the branched-chain ketoacid dehydrogenase complex. Renal clearance matters only when the filtered load exceeds tubular reabsorption, which at these doses it never does.
The oral barrier is the only reason to inject, and it applies to exactly one component. The gut wall and liver extract a large fraction of an oral arginine dose before it reaches the systemic circulation, which is the whole basis of the citrulline workaround Maric 2021. For leucine, glutamine, glycine and taurine, oral bioavailability is high and first-pass metabolism is not the limiting step — total intake is.
Numbers, so the claim is checkable. Free plasma amino acid concentrations sit in the tens to hundreds of micromolar; whole-body flux for a single amino acid runs in the tens of grams per day. A 50–100 mg injected bolus is roughly 0.1–0.5% of daily flux for the components it contains. A subcutaneous depot of a small, water-soluble, uncharged-at-pH-7 molecule is absorbed by capillary uptake with a time-to-peak measured in 15–45 minutes and is essentially complete; that is why subcutaneous dosing of small drugs works at all El Khoury 2022.
The injectable comparator, stated the honest way round. Compare the injection not to nothing but to food. Twenty grams of whey, swallowed, puts more of every one of these eight amino acids into plasma than the vial does, for about a dollar, and the appearance curve is measurable de Marco Castro 2022. The one thing the injection buys that food cannot is arginine that has not met arginase.
What would have to be true, and how you would know it was not
Three predictions. Two are cheap draws nobody has run on this product, and the third is the one that argues against it.
1. A CMP should not move, and that is the test of the dose. Blood urea nitrogen is the end product of amino acid nitrogen disposal, and it is genuinely sensitive to protein load — a large real change in daily amino acid intake shifts it. Order a CMP (which carries BUN and creatinine) at baseline and again at 8 weeks on a stable diet. Prediction: flat. If BUN is genuinely unchanged, the injected nitrogen load is below the resolution of the assay, which is the arithmetic above confirmed in a person. If it rises, either the vial is far more concentrated than an isotonic solution can be, or the diet changed.
2. ADMA is the honest read-out for the arginine arm, and it is the one nobody orders. Asymmetric dimethylarginine is the endogenous inhibitor of nitric oxide synthase, and the arginine-to-ADMA ratio is the variable that actually predicts NO availability — not arginine alone. Draw ADMA at baseline and at 8–12 weeks. Prediction: unchanged, because ADMA is set by PRMT methylation and DDAH clearance, not by substrate supply. If ADMA falls on an arginine-containing injectable, that is a genuinely new observation about this class of product and worth writing down.
3. The prediction that cuts against the product: fasting insulin and hs-CRP should be flat, and if they are, there is nothing left for the blend to be doing. The recovery claim rests on inflammation and on anabolic signaling. Draw fasting insulin and hs-CRP before and after 8 weeks. Flat on both, plus a flat CMP, plus unchanged ADMA, and the remaining possible mechanisms are the placebo response and the training that accompanied it — both real, neither pharmacological. A page that predicted only the good outcome would be an advertisement.
What nobody has tested yet
Four experiments nobody has run on an injectable amino acid blend, each of which is cheap and would settle something.
Nobody has published the actual composition in milligrams. That is the single most important missing number on this page. Every claim above is built from a tonicity ceiling rather than from a certificate of analysis, because no per-component milligram figure is publicly available. A third-party amino acid analysis of one vial — a routine, inexpensive assay — would replace the estimate with a fact and would settle the whole argument in either direction.
Nobody has measured a plasma appearance curve for a subcutaneous mixed amino acid bolus. Four timed draws after one injection, in one person, measuring free leucine and arginine, is a single afternoon's work and would produce the first kinetic data this product class has ever had. The oral comparator curve already exists de Marco Castro 2022.
Nobody has tested whether subcutaneous arginine beats oral citrulline. This is the one head-to-head that would justify the needle, it has an obvious endpoint — plasma arginine over four hours, and the arginine-to-ADMA ratio — and it has never been done for any product of this shape.
Nobody has looked at whether the injection site itself does anything. Local subcutaneous delivery of a hypertonic solution creates a small, sterile inflammatory depot. Whether any part of the reported “recovery” effect is a local response rather than a systemic one is testable with a contralateral saline injection and a symptom diary, and it is the kind of experiment self-reporting readers could actually run.
Amino Recovery Blend — its own safety story, not its class's
This blend's risk story is about the solution, not the molecules. The class safety block below is written for peptides. Amino acids are not peptides, and their risks come from three specific places: tonicity, sterility and the counter-ions.
Tonicity is the real one, and it is mechanical. A concentrated free amino acid solution is hypertonic. Injected subcutaneously, hypertonic fluid draws water into the depot, which produces the sting, the wheal and the slow-resolving lump people describe. The subcutaneous route tolerates large volumes of ISOTONIC fluid well — that is the entire basis of clinical subcutaneous hydration Broadhurst 2020 — so the volume is not the problem and the concentration is. Smaller volume at the same concentration does not fix it; it only makes the depot smaller.
pH is the second one, and it is why some vials burn more than others. Arginine is strongly basic (its guanidinium side chain has a pKa above 12) and glutamine is unstable in solution, cyclizing to pyroglutamate and releasing ammonia over time, faster when warm. A blend containing both is therefore a solution whose pH and composition DRIFT with storage. That is a formulation fact rather than a scare: it means the sting and the potency of a vial at week six are not necessarily what they were at week one, and there is no way for a buyer to check.
The population who should not read past this paragraph. Anyone with reduced kidney function is handling a nitrogen load with a smaller margin, and the honest thing to say about an unlabeled nitrogen-containing injectable in that setting is that the dose is unknown, the arithmetic above is an estimate, and the safe move is a conversation with the clinician who manages the kidney — not a guess from a vault page. This is education about mechanism, not a recommendation for use.
And the risk that is genuinely low, said plainly so the page is not alarmist. These are dietary constituents at doses far below dietary intake. There is no receptor to desensitize, no enzyme to induce, no withdrawal, and no interaction with the compounds this blend is usually stacked with. The realistic downside is a sore injection site, a contaminated vial, and money.
Sources read for this page
- Maric S, et al. Citrulline, Biomarker of Enterocyte Functional Mass and Dietary Supplement. Metabolism, Transport, and Current Evidence for Clinical Use. Nutrients 2021 · PMID 34444954
- Ling ZN, et al. Amino acid metabolism in health and disease. Signal Transduction and Targeted Therapy 2023 · PMID 37699892
- de Marco Castro E, et al. Peripheral Amino Acid Appearance Is Lower Following Plant Protein Fibre Products, Compared to Whey Protein and Fibre Ingestion, in Healthy Older Adults despite Optimised Amino Acid Profile. Nutrients 2022 · PMID 36615694
- Martin-Cantero A, et al. Factors influencing the efficacy of nutritional interventions on muscle mass in older adults: a systematic review and meta-analysis. Nutrition Reviews 2021 · PMID 33031516
- Broadhurst D, et al. Subcutaneous hydration and medications infusions (effectiveness, safety, acceptability): A systematic review of systematic reviews. PLoS One 2020 · PMID 32833979
- El Khoury J, et al. Evaluation of efficacy and safety of subcutaneous acetaminophen in geriatrics and palliative care (APAPSUBQ). BMC Palliative Care 2022 · PMID 35346136
Amino Recovery Blend — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- A repair-peptide combination. Check the vendor's stated composition against anything you already run — overlap in this category is the norm, not the exception.
- *the repair-peptide arm:* Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- *the repair-peptide arm:* There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- *the repair-peptide arm:* The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
- The risk that belongs to the blend rather than any component: double-dosing. If you already run any of the peptides above separately, adding this blend means two doses of it — and almost nobody counts a blend's arms against what is already in their protocol. Read the composition against your current stack before the first injection.
What has actually been reported
- *the repair-peptide arm:* Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- *the repair-peptide arm:* Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- *the repair-peptide arm:* Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- *the repair-peptide arm:* Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- *the repair-peptide arm:* Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- *the repair-peptide arm:* One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- *the repair-peptide arm:* Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- *the repair-peptide arm:* Active or recently treated malignancy — the angiogenesis reasoning.
- *the repair-peptide arm:* Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- *the repair-peptide arm:* Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Amino Recovery Blend — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Amino Recovery Blend moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
From the repair-peptide arm. If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
From the repair-peptide arm. Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
A repair-peptide combination. The interference picture is the healing one; check the vendor's stated composition against anything you are already running, because overlap in this category is the norm.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Storage and travel
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Amino Recovery Blend in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Amino Recovery Blend
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Amino Recovery Blend — frequently asked questions
What is Amino Recovery Blend?
Amino Recovery Blend (EAA/amino stack (Arg, Citrulline, Ornithine, Glutamine, Glycine, Lysine, BCAA 2:1:1, Taurine)) is a healing & recovery research compound. Recovery amino-acid matrix — arginine/citrulline/ornithine drive nitric oxide and the urea cycle, BCAAs and glutamine support muscle protein synthesis and recovery, glycine and taurine add cellular and antioxidant support.
Is the full Amino Recovery Blend protocol on this page?
The reported research dose is on this page, along with how Amino Recovery Blend works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Amino Recovery Blend?
Amino Recovery Blend has an approximate half-life of Varies by component, which is part of what determines how often it's dosed.
What's the evidence behind Amino Recovery Blend?
Current evidence level: Blend (component-based). Amino Recovery Blend is offered for research purposes only and is not an approved medicine.
What Amino Recovery Blend is used for
Amino Recovery Blend appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.